Value of 99m Tc-MIBI SPECT/CT in the localization of recurrent lesions in patients with suspected recurrent parathyroid carcinoma.
Humans
Parathyroid Neoplasms
/ diagnostic imaging
Technetium
Retrospective Studies
Tomography, Emission-Computed, Single-Photon
/ methods
Neoplasm Recurrence, Local
/ diagnostic imaging
Technetium Tc 99m Sestamibi
Single Photon Emission Computed Tomography Computed Tomography
Sensitivity and Specificity
Radiopharmaceuticals
Journal
Nuclear medicine communications
ISSN: 1473-5628
Titre abrégé: Nucl Med Commun
Pays: England
ID NLM: 8201017
Informations de publication
Date de publication:
01 Jan 2023
01 Jan 2023
Historique:
pubmed:
29
11
2022
medline:
16
12
2022
entrez:
28
11
2022
Statut:
ppublish
Résumé
Accurate preoperative localization of tumor-bearing lesions is crucial for the successful surgical management of suspected recurrent parathyroid carcinoma. The purpose of this study was to evaluate the diagnostic value of 99m-technetium-labeled methoxyisobutylisonitrile ( 99m Tc-MIBI) single-photon emission computed tomography/computed tomography (SPECT/CT) and cervical ultrasound, individually and in combination, for preoperative localization of recurrent/metastatic lesions. We also analyzed the value of 99m Tc-MIBI SPECT/CT in detecting ectopic lesions in patients with suspected recurrent parathyroid carcinoma. Twenty-nine patients with suspected recurrent parathyroid carcinoma were included in this retrospective cohort study. Patients underwent preoperative 99m Tc-MIBI SPECT/CT and cervical ultrasound. The reference standard was postsurgical histopathology. The sensitivity, specificity, positive predictive value (PPV), negative predictive value, and accuracy of the two diagnostic modalities alone and in combination were analyzed. Of the 29 patients, histopathological results revealed 48 metastases/recurrent lesions in 26 patients. The diagnostic value of 99m Tc-MIBI SPECT/CT, cervical ultrasound, and the two modalities in combination were compared for the 27 patients who underwent new cervical surgery. Patient-level analysis of the combined use of 99m Tc-MIBI SPECT/CT and cervical ultrasound had the highest sensitivity (100.00%) and accuracy (96.30%). At the lesion level, 99m Tc-MIBI SPECT/CT had the highest specificity and PPV, at 100.00% respectively, whereas the combined use of 99m Tc-MIBI SPECT/CT and cervical ultrasound had the highest sensitivity, at 97.62%. Moreover, 99m Tc-MIBI SPECT/CT detected six ectopic lesions, and five of them showed increased 99m Tc-MIBI uptake. The combined use of 99m Tc-MIBI SPECT/CT and cervical ultrasound is the most efficient strategy in the diagnosis of parathyroid carcinoma relapse, whereas 99m Tc-MIBI SPECT/CT is the preferred method for localizing and analyzing cervical and extra-cervical lesions before the new surgery.
Identifiants
pubmed: 36437540
doi: 10.1097/MNM.0000000000001641
pii: 00006231-202301000-00003
doi:
Substances chimiques
Technetium
7440-26-8
Technetium Tc 99m Sestamibi
971Z4W1S09
Radiopharmaceuticals
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
18-26Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Lenschow C, Schrägle S, Kircher S, Lorenz K, Machens A, Dralle H, et al. NEKAR study group. Clinical presentation, treatment, and outcome of parathyroid carcinoma: results of the NEKAR retrospective international multicenter study. Ann Surg 2022; 275:e479–e487.
Goswamy J, Lei M, Simo R. Parathyroid carcinoma. Curr Opin Otolaryngol Head Neck Surg 2016; 24:155–162.
Rodrigo JP, Hernandez-Prera JC, Randolph GW, Zafereo ME, Hartl DM, Silver CE, et al. Parathyroid cancer: an update. Cancer Treat Rev 2020; 86:102012.
Cetani F, Pardi E, Marcocci C. Update on parathyroid carcinoma. J Endocrinol Invest 2016; 39:595–606.
Salcuni AS, Cetani F, Guarnieri V, Nicastro V, Romagnoli E, de Martino D, et al. Parathyroid carcinoma. Best Pract Res Clin Endocrinol Metab 2018; 32:877–889.
Ryhänen EM, Leijon H, Metso S, Eloranta E, Korsoff P, Ahtiainen P, et al. A nationwide study on parathyroid carcinoma. Acta Oncol 2017; 56:991–1003.
Harari A, Waring A, Fernandez-Ranvier G, Hwang J, Suh I, Mitmaker E, et al. Parathyroid carcinoma: a 43-year outcome and survival analysis. J Clin Endocrinol Metab 2011; 96:3679–3686.
Schulte KM, Talat N. Diagnosis and management of parathyroid cancer. Nat Rev Endocrinol 2012; 8:612–622.
Wei CH, Harari A. Parathyroid carcinoma: update and guidelines for management. Curr Treat Options Oncol 2012; 13:11–23.
Petranović Ovčariček P, Giovanella L, Carrió Gasset I, Hindié E, Huellner MW, Luster M, et al. The EANM practice guidelines for parathyroid imaging. Eur J Nucl Med Mol Imaging 2021; 48:2801–2822.
Zarei A, Karthik S, Chowdhury FU, Patel CN, Scarsbrook AF, Vaidyanathan S. Multimodality imaging in primary hyperparathyroidism. Clin Radiol 2022; 77:e401–e416.
Machado NN, Wilhelm SM. Parathyroid cancer: a review. Cancers (Basel) 2019; 11:1676.
Chen Z, Fu J, Shao Q, Zhou B, Wang F. 99mTc-MIBI single photon emission computed tomography/computed tomography for the incidental detection of rare parathyroid carcinoma. Medicine (Baltim) 2018; 97:e12578.
Christakis I, Vu T, Chuang HH, Fellman B, Figueroa A, Williams MD, et al. The diagnostic accuracy of neck ultrasound, 4D-Computed tomography and sestamibi imaging in parathyroid carcinoma. Eur J Radiol 2017; 95:82–88.
Kebebew E, Arici C, Duh QY, Clark OH. Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Arch Surg 2001; 136:878–885.
Clark P, Wooldridge T, Kleinpeter K, Perrier N, Lovato J, Morton K. Providing optimal preoperative localization for recurrent parathyroid carcinoma: a combined parathyroid scintigraphy and computed tomography approach. Clin Nucl Med 2004; 29:681–684.
Mete O, Wenig BM. Update from the 5th edition of the World Health Organization classification of head and neck tumors: overview of the 2022 WHO classification of head and neck neuroendocrine neoplasms. Head Neck Pathol 2022; 16:123–142.
Ferraro V, Sgaramella LI, Di Meo G, Prete FP, Logoluso F, Minerva F, et al. Current concepts in parathyroid carcinoma: a single centre experience. BMC Endocr Disord 2019; 19:46.
Marcocci C, Cetani F, Rubin MR, Silverberg SJ, Pinchera A, Bilezikian JP. Parathyroid carcinoma. J Bone Miner Res 2008; 23:1869–1880.
Machens A, Lorenz K, Dralle H. Parathyroid hormone levels predict long-term outcome after operative management of parathyroid cancer. Horm Metab Res 2017; 49:485–492.
Iacobone M, Lumachi F, Favia G. Up-to-date on parathyroid carcinoma: analysis of an experience of 19 cases. J Surg Oncol 2004; 88:223–228.
Busaidy NL, Jimenez C, Habra MA, Schultz PN, El-Naggar AK, Clayman GL, et al. Parathyroid carcinoma: a 22-year experience. Head Neck 2004; 26:716–726.
Evangelista L, Sorgato N, Torresan F, Boschin IM, Pennelli G, Saladini G, et al. FDG-PET/CT and parathyroid carcinoma: review of literature and illustrative case series. World J Clin Oncol 2011; 2:348–354.
Gardner CJ, Wieshmann H, Gosney J, Carr HM, Macfarlane IA, Cuthbertson DJ. Localization of metastatic parathyroid carcinoma by 18F FDG PET scanning. J Clin Endocrinol Metab 2010; 95:4844–4845.
Huber GF, Hüllner M, Schmid C, Brunner A, Sah B, Vetter D, et al. Benefit of 18F-fluorocholine PET imaging in parathyroid surgery. Eur Radiol 2018; 28:2700–2707.
Deandreis D, Terroir M, Al Ghuzlan A, Berdelou A, Lacroix L, Bidault F, et al. ¹ 8 Fluorocholine PET/CT in parathyroid carcinoma: a new tool for disease staging? Eur J Nucl Med Mol Imaging 2015; 42:1941–1942.
Thanseer NTK, Parihar AS, Sood A, Bhadada SK, Dahiya D, Singh P, et al. Evaluation of recurrent parathyroid carcinoma: a new imaging tool in uncommon entity. World J Nucl Med 2019; 18:198–200.
Melloul M, Paz A, Koren R, Cytron S, Feinmesser R, Gal R. 99mTc-MIBI scintigraphy of parathyroid adenomas and its relation to tumour size and oxyphil cell abundance. Eur J Nucl Med 2001; 28:209–213.
Ning Y, Chen D, Huang Z, Lou C. Diagnostic value of clinical parameters and parathyroid scintigraphy for asymptomatic primary hyperparathyroidism. Hell J Nucl Med 2020; 23:148–157.
Campennì A, Giovinazzo S, Pignata SA, Di Mauro F, Santoro D, Curtò L, et al. Association of parathyroid carcinoma and thyroid disorders: a clinical review. Endocrine 2017; 56:19–26.